We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shire sold its mRNA therapy platform to RaNA Therapeutics in return for an undisclosed equity stake, as well as future milestones and royalties on products developed with the technology, RaNA announced Wednesday.